A retrospective review of patients receiving primary ADT for metastatic prostate cancer by Sasaki et al. [46] indicated that a lower PSA nadir with ADT and a longer time to PSA nadir (>9 months) was associated with improved overall survival in prostate cancer patients with bony metastases [46]. This evidence concerns the gene KLK3 and metastatic prostate carcinoma.